ICGi015-A
General
Cell Line |
|
| hPSCreg name | ICGi015-A |
| Cite as: | ICGi015-A (RRID:CVCL_XY44) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease CBIGi007-A-1 (IPSC0009, TMEM175 Q65Q homozygous correction) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi007-A-2 (IPSC0010, TMEM175 P65P homozygous disease) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi009-A-1 (IPSC0013, TMEM175 M393T homozygous correction) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi013-A-1 (LRRK2 M1646T correction, IPSC0018) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi027-A-1 (IPSC0039, LRRK2 G2385R (CBIGi027) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease CBIGi005-A (IPSC0003, LRRK2 G2019S) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi007-A (IPSC0008, TMEM175 Q65P heterozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi009-A (IPSC0012, TMEM175 M393T homozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi013-A (IPSC0017, LRRK2 M1646T (heterozygous)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi015-A (IPSC0020, LRRK2 N551K-R1398H-K1423K (protective haplotype)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi016-A (IPSC0021, Parkin homozygous deletion between exon 3 and 4) Donor's gene variants: PRKN, PRKN Donor diseases: Parkinson Disease CBIGi009-B (TMEM175 M393T homozygous (CBIGi009), IPSC0033) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi027-A (LRRK2 G2385R (CBIGi027), IPSC0037) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi039-A-1 (IPSC0051, LRRK2 R1441H(CBIGi039-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi041-A-1 (IPSC0054, GBA L444P (CBIGi041-A) correction) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi042-A-1 (GBA E326K (CBIGi042-A) correction, IPSC0056) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi044-A-1 (IPSC0059, LRRK2 N551K (CBIGi044-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease |
| Last update | 20th April 2022 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
External Databases |
|
| BioSamples | SAMEA6098039 |
| Cellosaurus | CVCL_XY44 |
| Wikidata | Q94313448 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://www.ncbi.nlm.nih.gov/sra/SRX6788805 |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA6098112 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Federal Center of Neurosurgery |
| Approval number | 1 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Federal Center of Neurosurgery |
| Approval number | 1 |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Addgene |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| Acta2 |
Yes |
Morphology
1 m6.6 dapi+a-sma.tif
Acta2 - green, DAPI - blue
In vitro spontaneous differentiation
| Marker | Expressed |
| NF200 |
Yes |
Morphology
2 m6.6 dapi+nf200.tif
NF200 - green, DAPI - blue
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.